Ono Pharmaceutical Company, Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ono Pharmaceutical Company, Ltd.
Following last year’s license pact with Arvelle in Europe and a US launch earlier this year, SK Biopharmaceuticals’ sizable deal with Ono now paves the way for the South Korean company to enter the Japanese market and further expand antiepileptic cenobamate’s global presence.
Switch consultant Susan Levy suggests drug firms temper enthusiasm for Rx-to-OTC switches with considering the costs NDAs generate and the histories of switches that haven’t been successes.
A new frontier for IO therapies in gastric/gastroesophageal cancers is opening up on positive data for two leading checkpoint inhibitors in first-line advanced disease where BMS’s Opdivo looks likely to have an advantage over Merck & Co’s Keytruda.
German reimbursement of COVID-19 confirmatory tests has been reduced by one third, a decision that has frustrated both the testing labs and the diagnostics manufacturers who jointly provided the basis of the system that kept the coronavirus to within manageable proportions nationally.
- Generic Drugs
- Other Names / Subsidiaries
- Ono Pharma Korea Co., Ltd., Ono Venture Investment Fund I, L.P., Ono Venture Investment, Inc., ONO Pharma UK Ltd.